Search Results - "KAHAN, B. D"

Sirolimus Therapy Predisposes to New-Onset Diabetes Mellitus After Renal Transplantation: A Long-Term Analysis of Various Treatment Regimens by Gyurus, E, Kaposztas, Z, Kahan, B.D

“…Abstract Purpose This retrospective analysis evaluated the impacts of sirolimus (SRL), cyclosporine (CsA), and steroids (S) on the occurrence, treatment, and…”
Get full text

Impact of rituximab therapy for treatment of acute humoral rejection by Kaposztas, Z., Podder, H., Mauiyyedi, S., Illoh, O., Kerman, R., Reyes, M., Pollard, V., Kahan, B.D.

“…:  Introduction:  Antibody mediated rejection (AMR) is associated with a greater incidence of allograft loss because traditional approaches ‐ pulse steroid or…”
Get full text

Pharmacology of Synergism Among Immunosuppressive Drugs for Transplantation by Kahan, BD

“…The pleiotropic toxicities of immunosuppressants have led clinicians to employ drug combinations using individually subtherapeutic doses. These combinations…”
Get full text

Fifty Years in the Vineyard of Transplantation: Looking Back by Kahan, B.D

“…Abstract The past 5 decades have documented remarkable advances in basic knowledge and clinical expertise in transplantation. The first 12 years of this half…”
Get full text

Fifteen Years of Clinical Studies and Clinical Practice in Renal Transplantation: Reviewing Outcomes With De Novo Use of Sirolimus in Combination With Cyclosporine by Kahan, B.D

“…Abstract Over the course of 15 years the use of sirolimus, a macrocyclic lactone, has evolved from an adjunct to calcineurin inhibitors (CNI) to the foundation…”
Get full text

Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody by KAHAN, B. D, RAJAGOPALAN, P. R, HALL, M

“…A double-blind, placebo-controlled phase III study was performed to assess whether basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody,…”
Get full text

Two-year results of multicenter phase III trials on the effect of the addition of sirolimus to Cyclosporine-based immunosuppressive regimens in renal transplantation by Kahan, B.D

“…Randomized clinical trials conducted over 24 months and including nearly 1300 renal transplant patients compared the efficacy and safety of two dose levels of…”
Get full text

New-Onset Diabetes After Renal Transplantation: Diagnosis, Incidence, Risk Factors, Impact on Outcomes, and Novel Implications by Kaposztas, Z, Gyurus, E, Kahan, B.D

“…Abstract Objective New-onset diabetes after transplantation (NODAT) is a multifactorial, complex metabolic disorder associated with impaired long-term graft…”
Get full text

Better Actual 10-Year Renal Transplant Outcomes of 80% Reduced Cyclosporine Exposure With Sirolimus Base Therapy Compared With Full Cyclosporine Exposure Without or With Concomittant Sirolimus Treatment by Pliszczynski, J, Kahan, B.D

“…Abstract Objective Retrospective analysis of 10-year outcomes of sirolimus (SRL) plus varying exposure to cyclosporine (CsA) in combination therapy for renal…”
Get full text

The place of sirolimus in kidney transplantation: Can we reduce calcineurin inhibitor renal toxicity? by Knight, R.J., Kahan, B.D.

“…Sirolimus, a macrocylic lactone, blocks T-cell activation by a mechanism of action distinct from calcineurin inhibitors (CNIs). Therefore, it may be expected…”
Get full text

Frontiers in Immunosuppression by Kahan, B.D

“…Abstract Because of the pleiotropic toxicities of available immunosuppressants, new approaches have employed agents that seek to mitigate nephrotoxicity. Phase…”
Get full text

Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in Caucasian recipients of mismatched primary renal allografts : A phase II trial by KAHAN, B. D, JULIAN, B. A, PESCOVITZ, M. D, VANRENTERGHEM, Y, NEYLAN, J

“…The novel agent sirolimus (SRL; Rapamune; rapamycin) inhibits the immune response by a mechanism distinct from those of calcineurin antagonists or…”
Get full text

Current Approaches to the Use of Sirolimus In Renal Transplantation by Kahan, B.D

“…Abstract Sirolimus, a macrolide with immunosuppressive properties, was introduced into clinical practice a decade ago. The optimal use of this drug remains…”
Get full text

Sirolimus: a ten-year perspective by Kahan, B.D

“…Sirolimus, a macrocyclic lactone that displays a novel mechanism of immunosuppressive action, is a critical-dose drug requiring therapeutic drug monitoring for…”
Get full text

Individualization of Immunosuppressive Therapy. III. Sirolimus Associated With a Reduced Incidence of Malignancy by Yakupoglu, Y.K., Buell, J.F., Woodle, S., Kahan, B.D.

“…We examined the occurrence of neoplasms among 1008 renal transplant recipients treated with a sirolimus-cyclosporine (CsA) ± prednisone (Pred) regimen. A…”
Get full text

Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients by Morrisett, J.D, Abdel-Fattah, G, Kahan, B.D

“…Sirolimus (Rapammune, rapamycin, RAPA) is a strong immunosuppressive agent that reduces kidney transplant rejection. Hyperlipidemia is a significant side…”
Get full text

Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients : Risk factors, incidence, progression, and management by HONG, J. C, KAHAN, B. D

“…Our study assessed the factors that predispose renal transplant recipients to the occurrence of thrombocytopenia and leukopenia, as well as the severity and…”
Get full text

Therapeutic drug monitoring of cyclosporine: 20 years of progress by Kahan, B.D

“…Since its introduction 20 years ago, cyclosporine (CyA), a powerful immunosuppressant with a narrow therapeutic window, remains the cornerstone of many drug…”
Get full text

Addition of induction therapy offsets the hazard of marked calcineurin minimization among renal transplant recipients treated with sirolimus by Kahan, B D, Benavides, C, Schoenberg, L, Podbielski, J, Green, C

“…We sought to examine the improvement in renal function with preserved immunosuppression consequent to reducing de novo cyclosporine (CsA) doses combined with…”
Get more information

Use of anti-CD25 monoclonal antibody in combination with rapamycin to eliminate cyclosporine treatment during the induction phase of immunosuppression by HONG, J. C, KAHAN, B. D

“…Cyclosporine and tacrolimus are associated with drug-induced renal dysfunction that may exacerbate recovery from ischemic injuries during the first month…”
Get full text